Home > Letters

CSOO writes letters to policymakers in response to legislation and regulations on issues relating to opioid overdose. Below, you can find an archive of letters CSOO has recently sent:

 

The Medicaid Reentry Act, H.R. 4005

The Medicaid Reentry Act would grant states limited new flexibility to restart benefits for Medicaid-eligible incarcerated individuals 30 days prior to release. With this flexibility, states would be able to facilitate access to medication treatment for inmates prior to release and better coordinate care with community providers, allowing for uninterrupted, evidence-based treatment for these individuals during a transition when they are at heightened risk of overdose and death.

 

Reinforcing Evidence-Based Standards Under Law in Treating Substance Abuse (RESULTS) Act of 2018, H.R. 5272

The RESULTS Act would ensure that federal grants intended to treat mental health and substance use disorders fund initiatives that are rooted in scientific evidence. The legislation would also establish a waiver mechanism for new or innovative treatments that may offer promise but have not established a full evidence base.

 

Substance Use Disorder Workforce Loan Repayment Act of 2018

The Substance Use Disorder Loan Repayment Act would create a more robust treatment workforce by helping clinicians who pursue full-time substance use disorder treatment jobs in high-need geographic areas repay their student loans.

 

Advancing Cutting-Edge (ACE) Research Act

The Advancing Cutting-Edge (ACE) Research Act would provide the National Institutes of Health (NIH) with additional tools and flexibility to support innovative medical research to combat the opioid crisis.

 

The Behavioral Health Coverage Transparency Act of 2018

The Behavioral Health Coverage Transparency Act would require issuers to disclose the analysis they perform in making parity determinations; require federal regulators to conduct random audits; and require the federal parity agencies to review denial rates for mental health versus medical claims. Additionally, it would create a central online portal so that people can access all information as a one-stop shop, and submit complaints and violations.

 

Addiction Treatment Access Improvement Act, H.R. 3692

The Addiction Treatment Access Improvement Act would codify the Final Rule issued by the Department of Health and Human Services (HHS) in July 2016 that raised the DATA 2000 patient limit for certain physicians to 275 patients, eliminating the sunset date for nurse practitioners’ (NPs) and physician assistants’ (PAs) prescribing authority for buprenorphine, and expanding the definition of ‘qualifying practitioner’ to include nurse anesthetists, clinical nurse specialists, and nurse midwives.